A9361

Artemether

≥98% (HPLC)

• Synonym(e): Dihydroartemisinin-methylether, Dihydroqinghaosu-methylether
• Empirische Formel (Hill-System): C₁₆H₂₆O₅
• CAS-Nummer: 71963-77-4
• Molekulargewicht: 298.37
• NACRES: NA.77
• PubChem Substance ID: 329771050
• UNSPSC Code: 51101908
• MDL number: MFCD00866205
• Assay: ≥98% (HPLC)
• Form: powder
• Quality level: 100

Eigenschaften

• Quality Level: 100
• assay: ≥98% (HPLC)
• form: powder
• optical activity: [α]/D +155 to +175°, c = 0.5 in methanol
• color: off-white to light brown
• solubility: DMSO: ≥20 mg/mL
• originator: Novartis
• storage temp.: room temp
• SMILES string: CO[C@H]1OC2O[C@@]3(C)CCC4[C@H](C)CCC([C@H]1C)[C@@]24OO3
• InChI: 1S/C16H26O5/c1-9-5-6-12-10(2)13(17-4)18-14-16(12)11(9)7-8-15(3,19-14)20-21-16/h9-14H,5-8H2,1-4H3/t9-,10-,11+,12+,13+,14-,15-,16-/m1/s1
• InChI key: SXYIRMFQILZOAM-HVNFFKDJSA-N

Beschreibung

General description

Artemisinin (ART) is a natural compound present in Artemisia annua, a traditional Chinese plant.

Application

Artemether has been used:

• as an anti-schistosomal compound to test it effect on the larval stages of S. mansoni
• to sensitize mouse embryonic fibroblasts (MEFs) and human osteosarcoma HT1080 cells to cysteine starvation (STV)-induced ferroptosis
• to stimulate islets and its effect on α to β transdifferentiation

Biochem/physiol Actions

Artemether is a methyl ether derivative of artemisinin. It is used against multi-drug resistant strains of the malaria parasite, Plasmodium falciparum, and shows potential in treatment of schistosomiasis.

Artemether is an anti-antimalarial compound.

Artemisinin possesses a highly reactive endoperoxide bridge, which is core for its therapeutic potential. The endoperoxide bond reacts with iron in the erythrocytes with malarial parasite. This leads to the generation of reactive oxygen species (ROS) directly targeting the parasite. Artemisinin also regulates ferroptosis in tumor cells. The α cell transcription factor Arx expression is reduced by artemether. Prolonged exposure of primary islets also resulted in loss if identity in endocrine cell types and their functionality.

Features and Benefits

This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Sicherheitshinweise

• pictograms: GHS02,GHS07
• signalword: Danger
• hcodes: H242,H302
• pcodes: P210 - P235 - P280 - P301 + P312 - P370 + P378 - P410
• Hazard Classifications: Acute Tox. 4 Oral - Org. Perox. D
• Lagerklasse: 5.2 - Organic peroxides and self-reacting hazardous materials
• wgk: WGK 3
• flash_point_f: No data available
• flash_point_c: No data available